Apellis Pharmaceuticals (APLS) M&A announcement summary

Deal rationale and strategic fit

• Acquisition adds two best-in-class, FDA-approved commercial-stage immunology products, SYFOVRE and EMPAVELI, expanding the growth portfolio and accelerating expansion into nephrology and rare diseases.

• Enhances nephrology capabilities, providing U.S. infrastructure and expertise to support future launches such as felzartamab.

• Broadens and diversifies revenue growth drivers, supporting a sustainable long-term growth strategy.

• Combines commercialization strengths and scientific expertise, leveraging Apellis' established teams to maximize product potential.

• Complements existing pipeline and supports strategic shift beyond neuroscience.

Financial terms and conditions

• Purchase price is $41 per share, totaling approximately $5.6 billion in cash, with contingent value rights (CVRs) up to $4 per share tied to SYFOVRE global net sales milestones between 2027 and 2031.

• Financed with about $3.6 billion cash on hand and $2 billion from revolving credit and bank loans, with plans to fully de-lever by end of 2027.

• Represents an 86% premium to the 90-day volume-weighted average stock price and a 35% premium to the 52-week high.

• Transaction expected to close in Q2 2026, subject to customary conditions and regulatory approvals.

• CVR payments are aspirational and not included in base case forecasts.

Synergies and expected cost savings

• Combined commercial infrastructure in nephrology and rare diseases will support launches and drive efficiencies.

• Integration of Apellis' talent and field capabilities expected to strengthen commercial readiness and accelerate expansion.

• Opportunity to leverage Apellis' nephrology sales force for felzartamab launch, reducing duplicative hiring.

• Significant proportion of Apellis employees to join, supporting product launches and ongoing operations.

• Potential for operational discipline and cost control post-integration.